Skip to main content
Cellbion Co., Ltd logo

Cellbion Co., Ltd — Investor Relations & Filings

Ticker · 308430 ISIN · KR7308430008 KO Manufacturing
Open in API
Filings indexed 56 across all filing types
Latest filing 2026-02-27 Proxy Solicitation & In…
Country KR South Korea
Listing KO 308430

About Cellbion Co., Ltd

http://www.cellbion.co.kr

Cellbion Co., Ltd. is a company engaged in the research, development, and commercialization of radiopharmaceuticals. It specializes in Radioligand Therapy (RLT), developing both therapeutic and diagnostic agents to address unmet medical needs, primarily in oncology. The company's pipeline features innovative treatments, including antibody-based approaches and radioactive probes for medical imaging. A key therapeutic candidate in its portfolio is Lu-177-DGUL. Cellbion's focus is on advancing the field of nuclear medicine through novel drug development.

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit shareholder votes for an upcoming General Meeting. It contains details about the meeting agenda (approval of financial statements, articles of incorporation changes, director/auditor compensation limits), information about the solicitors, and instructions for voting. This aligns perfectly with the 'Proxy Solicitation & Information Statement' category.
2026-02-27 Korean
투자판단관련주요경영사항 (Lu-177-DGUL(포큐보타이드 사테트라세탄) 식품의약품안전처 품목 조건부 허가 신청)
Regulatory Filings Classification · 95% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding a 'Major Management Matter' (투자판단 관련 주요경영사항). It details the company's application for conditional marketing authorization of a new drug (Lu-177-DGUL) with the Ministry of Food and Drug Safety (MFDS). Since it is a specific regulatory disclosure of a material corporate event (drug approval application) rather than a periodic financial report, a transcript, or a simple announcement of a report, it falls under the category of general regulatory filings.
2025-12-30 Korean
투자판단관련주요경영사항(임상시험계획승인신청등결정) (전이성 거세 저항성 전립선암 환자에서 Lutetium(177Lu) DGUL(포큐보타이드) 과 Pembrolizumab(키트루다) 병용요법의 제1상 임상시험계획승인(IND))
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Selbion) regarding the approval of a Phase 1 clinical trial (IND) by the Ministry of Food and Drug Safety (MFDS). It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) in the Korean stock market (KOSPI/KOSDAQ). Since it details a specific regulatory event (clinical trial approval) and does not fit into the other specific categories like financial reports or shareholder meetings, it is classified as a general regulatory filing.
2025-09-12 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) meeting (기업설명회). It provides details such as the date, time, location, target audience, and purpose of the meeting. It also mentions that the IR materials will be posted on the Korea Exchange's disclosure system. Since this is an announcement of an event rather than the presentation slides themselves, and it fits the criteria for a regulatory announcement regarding corporate activities, it is classified as a Regulatory Filing (RNS).
2025-09-09 Korean
투자판단관련주요경영사항(임상시험결과) (표준요법에 실패한 전이성 거세저항성 전립선암 환자에서 Lu177DGUL의 국내 임상 제2상 Topline data 수령)
Regulatory Filings Classification · 100% confidence The document is a formal regulatory disclosure from a Korean company (Selbion) regarding the results of a Phase 2 clinical trial. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) required by the Korea Exchange (KRX). Since it details specific clinical trial outcomes (Topline data) rather than being a general report announcement or a financial statement, it falls under the category of regulatory filings for material corporate events.
2025-09-04 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company 'Cellbion' (셀비온), covering the period from January 1, 2025, to June 30, 2025. It contains detailed financial information, business operations, management discussions, and corporate governance details, which are characteristic of an interim financial report. According to the provided definitions, a comprehensive financial report for a period shorter than a full fiscal year is classified as an Interim / Quarterly Report (IR). H1 2025
2025-08-13 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.